Engineered immune cells take aim at HPV-Positive cancers
NCT ID NCT03578406
First seen Jan 21, 2026 · Last updated Jun 19, 2026 · Updated 28 times
Summary
This early-stage trial tested a new type of cell therapy for people with HPV-positive head & neck or cervical cancer. The treatment uses a patient's own immune cells, engineered to recognize and attack HPV-infected cancer cells. Some patients also received cells that produce an anti-PD1 molecule to help the immune cells work better. The main goal was to find a safe dose, and only 9 people took part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Qingzhu Jia
Chongqing, Chongqing Municipality, 400037, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HPV E6-specific TCR-T cells
What this could lead to
If it works, this could point toward a new treatment option for HPV-positive head & neck or cervical cancers that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 9 participants, so it is too small to prove effectiveness. The approach may not work well in solid tumors, and there are risks from the cell therapy itself.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.